Relay Therapeutics Inc (NASDAQ:RLAY) shares, rose in value, with the stock price down by -1.31% to the previous day’s close as strong demand from buyers drove the stock to $5.64.
Actively observing the price movement in the last trading, the stock closed the session at $5.71, falling within a range of $5.6 and $5.755. The value of beta (5-year monthly) was 1.646. Referring to stock’s 52-week performance, its high was $12.14, and the low was $5.70. On the whole, RLAY has fluctuated by -13.17% over the past month.
With the market capitalization of Relay Therapeutics Inc currently standing at about $915.47 million, investors are eagerly awaiting this quarter’s results, scheduled for in December.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 80k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RLAY’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of RLAY currently trading nearly -11.57% and -18.40% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 32.02, while the 7-day volatility ratio is showing 5.33% which for the 30-day chart, stands at 5.62%. Furthermore, Relay Therapeutics Inc (RLAY)’s beta value is 1.65, and its average true range (ATR) is 0.40.
A comparison of Relay Therapeutics Inc (RLAY) with its peers suggests the former has fared considerably weaker in the market. RLAY showed an intraday change of -1.31% in last session, and over the past year, it shrunk by -14.62%%.
Data on historical trading for Relay Therapeutics Inc (NASDAQ:RLAY) indicates that the trading volumes over the past 10 days have averaged 1.17 and over the past 3 months, they’ve averaged 1.94 million. According to company’s latest data on outstanding shares, there are 127.46 million shares outstanding.
Nearly 25.73% of Relay Therapeutics Inc’s shares belong to company insiders and institutional investors own 55.87% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 11.86 million shares as on 2024-10-15, resulting in a short ratio of 6.16. According to the data, the short interest in Relay Therapeutics Inc (RLAY) stood at 891.00 of shares outstanding as of 2024-10-15; the number of short shares registered in 2024-09-13 reached 9.92 million. The stock has fallen by -48.82% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RLAY stock heading into the next quarter.
